Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network
Authors' conclusion
Patients with glucagonoma had prolonged survival, even in the presence of metastases at diagnosis. Curative-intent surgery should always be considered. Chemotherapy, peptide receptor radionuclide therapy, or liver-directed therapy seems to provide both substantial antitumor and antisecretory efficacies.
Study context
- Population
- Patients with glucagonoma (≥1 major criterion: NME, recent-onset diabetes and/or weight loss ≥5 kg, with glucagonemia >2× upper limit of normal or positive glucagon immunostaining); French Group of Endocrine Tumors and ENDOCAN-RENATEN network
- Participants
- 38 patients
- Outcome
- Characteristics, treatment efficacy and survival
Methodological detailsnational
- National
Main finding
As reported in the abstract
- Median age
- 58.7 yo
- Primary pancreatic neuroendocrine tumor (PanNET) in tail
- 68.4%
- Synchronous metastases
- 63.2%
- Median Ki-67 index
- 3%
- NME at diagnosis
- 86.8%
- Weight loss at diagnosis
- 68.4%
- Diabetes at diagnosis
- 50%
- Surgery of primary PanNET
- 76.3%
- Surgery with curative intent
- 61.5%
- Complete resolution of NME after surgery
- 93.8% (n = 15/16)
- Secretory response with surgery of metastases
- 85.7% (n = 6/7)
- Secretory response with chemotherapy
- 85.7% (n = 6/7)
- Secretory response with liver-directed therapy
- 75% (n = 6/8)
- Secretory response with SSA
- 60% (n = 6/10)
- Longest time to next treatment (TTNT), all lines combined: chemotherapy
- 20.2 months
- Median overall survival (OS)
- 17.3 years
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| OS by Ki-67 index >3%Ki-67 >3%vs Ki-67 ≤3%Shorter OS with Ki-67 >3% | 5.27 (1.11–24.96) | P = 0.036 | |
| 0.050.21520Hazard ratio (log scale) |
Original publication
Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network. Eur J Endocrinol. Published 1 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →